Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2003 Apr 17;13(8):1425-8.

Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors.

Author information

1
Department of Discovery Chemistry, Pfizer Global Research and Development, Sandwich Laboratories (IPC351), Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK. graham_maw@sandwich.pfizer.com

Abstract

The SAR of a series of beta-carboline derived type 5 phosphodiesterase inhibitors has been explored and we have discovered compounds with excellent levels of PDE5 potency and selectivity over PDE6. However, the series exhibits low levels of selectivity over PDE11, a phosphodiesterase with unknown function.

PMID:
12668004
DOI:
10.1016/s0960-894x(03)00159-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center